17 alpha-hydroxylase deficiency epidemiology and demographics

Jump to navigation Jump to search

Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17 alpha-hydroxylase deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17 alpha-hydroxylase deficiency epidemiology and demographics

CDC on 17 alpha-hydroxylase deficiency epidemiology and demographics

17 alpha-hydroxylase deficiency epidemiology and demographics in the news

Blogs on 17 alpha-hydroxylase deficiency epidemiology and demographics

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency

Risk calculators and risk factors for 17 alpha-hydroxylase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals. Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.[1]

Epidemiology and Demographics

Incidence

  • The incidencee of congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals.[2]

Age

  • Patients of all age groups may develop congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.

Gender

  • Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency affects male and female equally.[1]

References

  1. 1.0 1.1 Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency. Wikipedia (2016. https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_17_alpha-hydroxylase_deficiency Accessed on February 4, 2016
  2. Auchus RJ (2015). "The classic and nonclassic concenital adrenal hyperplasias". Endocr Pract. 21 (4): 383–9. doi:10.4158/EP14474.RA. PMID 25536973.


Template:WikiDoc Sources